MedTrace Logo

Remimazolam and Remifentanil Without Neuromuscular Blocking Agent

NCT05025410 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 38

Last updated 2022-04-25

No results posted yet for this study

Summary

Remimazolam is a novel drug approved for induction and maintenance of general anesthesia. This study aims to check the appropriate dose and patient response by administering remimazolam and remifentanil in surgery that does not require a neuromuscular blocking agents.

Conditions

  • Myoma;Uterus
  • Polyp Endometrium
  • Unspecified Condition Associated With Female Genital Organs and Menstrual Cycle

Interventions

DRUG

Remimazolam

Loading for anesthesia induction: Remimazolam 6 mg/kg/h until loss of consciousness Continuous infusion for anesthesia maintenance: Remimazolam 1-2 mg/kg/h under the Bispectral index monitoring

Sponsors & Collaborators

  • Seoul National University Bundang Hospital

    lead OTHER

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2022-01-31
Completion
2022-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05025410 on ClinicalTrials.gov